Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/80239
Title:
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.
Authors:
Leonard, P; Seymour, M T; James, Roger D; Hochhauser, D; Ledermann, J A
Abstract:
We investigated the activity of irinotecan given with a more convenient modified bimonthly de Gramont regimen of bolus and infusional 5-fluorouracil [IrMdG] in advanced or metastatic colorectal cancer in the first and second line setting. Irinotecan 180 mg m(-2) was infused over 90 min. L-folinic acid 175 mg or d,l folinic acid 350 mg was given over 2 h followed by a bolus of 5-fluorouracil (400 mg m(-2)) and a 46 h continuous infusion of 5-fluorouracil (2.4-2.8 g m(-2)). Forty-six previously untreated patients (Group A) and 36 who had received 5-fluorouracil for metastatic disease (Group B) were recruited. Seventy-eight patients were evaluable for response. A partial response was seen in 13 out of 43 (30% [95%CI 28.1-31.9%]) in Group A and 8/35 (23% [95% CI 17.9-28.1%]) in Group B. 40% (95%CI 38.1-41.9%) of Group A and 26% (95% CI 20.9-31.1%) of Group B patients achieved disease stabilisation. The median progression free survival from the start of this treatment was 7 months (95% CI 4.4-9.6 months) in Group A and 5 months (95% CI 2.8-7.2 months) in Group B. Median overall survival was 14 months (95% CI 9.0-18.9) in Group A and 11 months (95% CI 5.9-16.1) in Group B. Grade 3-4 toxicity in both treatment groups were similar; leucopenia 17% and diarrhoea 7-8%. Grade 3-4 mucositis was not seen and severe alopecia affected only three patients. IrMdG is an active and well-tolerated regimen for both the first and second line treatment of advanced colorectal cancer.
Affiliation:
Royal Free and University College Medical School, UCL, London, UK.
Citation:
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. 2002, 87 (11):1216-20 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
18-Nov-2002
URI:
http://hdl.handle.net/10541/80239
DOI:
10.1038/sj.bjc.6600641
PubMed ID:
12439708
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLeonard, P-
dc.contributor.authorSeymour, M T-
dc.contributor.authorJames, Roger D-
dc.contributor.authorHochhauser, D-
dc.contributor.authorLedermann, J A-
dc.date.accessioned2009-09-08T10:23:36Z-
dc.date.available2009-09-08T10:23:36Z-
dc.date.issued2002-11-18-
dc.identifier.citationPhase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. 2002, 87 (11):1216-20 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid12439708-
dc.identifier.doi10.1038/sj.bjc.6600641-
dc.identifier.urihttp://hdl.handle.net/10541/80239-
dc.description.abstractWe investigated the activity of irinotecan given with a more convenient modified bimonthly de Gramont regimen of bolus and infusional 5-fluorouracil [IrMdG] in advanced or metastatic colorectal cancer in the first and second line setting. Irinotecan 180 mg m(-2) was infused over 90 min. L-folinic acid 175 mg or d,l folinic acid 350 mg was given over 2 h followed by a bolus of 5-fluorouracil (400 mg m(-2)) and a 46 h continuous infusion of 5-fluorouracil (2.4-2.8 g m(-2)). Forty-six previously untreated patients (Group A) and 36 who had received 5-fluorouracil for metastatic disease (Group B) were recruited. Seventy-eight patients were evaluable for response. A partial response was seen in 13 out of 43 (30% [95%CI 28.1-31.9%]) in Group A and 8/35 (23% [95% CI 17.9-28.1%]) in Group B. 40% (95%CI 38.1-41.9%) of Group A and 26% (95% CI 20.9-31.1%) of Group B patients achieved disease stabilisation. The median progression free survival from the start of this treatment was 7 months (95% CI 4.4-9.6 months) in Group A and 5 months (95% CI 2.8-7.2 months) in Group B. Median overall survival was 14 months (95% CI 9.0-18.9) in Group A and 11 months (95% CI 5.9-16.1) in Group B. Grade 3-4 toxicity in both treatment groups were similar; leucopenia 17% and diarrhoea 7-8%. Grade 3-4 mucositis was not seen and severe alopecia affected only three patients. IrMdG is an active and well-tolerated regimen for both the first and second line treatment of advanced colorectal cancer.en
dc.language.isoenen
dc.subjectDiarrhoeaen
dc.subjectColorectal Canceren
dc.subjectCancer Metastasisen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCamptothecin-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshDiarrhea-
dc.subject.meshDisease-Free Survival-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshFemale-
dc.subject.meshFluorouracil-
dc.subject.meshHumans-
dc.subject.meshInfusions, Intravenous-
dc.subject.meshInjections, Intravenous-
dc.subject.meshLeucovorin-
dc.subject.meshLeukopenia-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshMouth Mucosa-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshStomatitis-
dc.subject.meshTreatment Outcome-
dc.titlePhase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.en
dc.typeArticleen
dc.contributor.departmentRoyal Free and University College Medical School, UCL, London, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.